Med24
metabolic-therapy 19. 10. 2026 • 2 min read • American heart journal (PubMed)

Design of Screening Cardiometabolic Opportunities Using Transformative Echocardiography Artificial Intelligence (SCOUT-Echo-AI).

BACKGROUND: Steatotic liver disease (SLD) is highly prevalent among individuals with cardiovascular disease, but often remains undiagnosed until advanced sequelae such as fibrotic liver disease and hepatocellular carcinoma develop. ​​Transthoracic echocardiography routinely captures incidental subcostal views of the...

Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)

The SCOUT-Echo-AI study is designed to evaluate the real-world impact of AI-enabled opportunistic liver disease screening. Steatotic liver disease (SLD) is frequently observed in individuals with cardiovascular disease, and often goes undiagnosed until advanced liver conditions such as fibrotic liver disease and hepatocellular carcinoma have developed. Routine transthoracic echocardiography captures subcostal liver views, which are currently not routinely utilized clinically. The EchoNet-Liver algorithm, utilizing artificial intelligence (AI), is employed to predict the presence of liver disease based on these echocardiograms. The study will involve an estimated enrollment of approximately 3,000 patients across six diverse U.S. healthcare systems: Kaiser Permanente Northern California, Stanford Healthcare, Cedars-Sinai Medical Center, University of California Los Angeles, Northwestern Medicine, and Massachusetts General Brigham. Participants will undergo routine echocardiograms, and the AI algorithm will analyze these images. Clinicians or participants will be notified of potential undiagnosed liver disease, triggering site-specific workflows for confirmation of the findings. The primary outcomes will measure the detection rates of SLD and fibrotic liver disease, alongside the positive predictive values within 12 months of the AI identification. Secondary outcomes will assess diagnostic accuracy relative to other gold-standard modalities, treatment initiation timelines, time to diagnosis, and the impact on other clinical events. Comparisons will be made against historical usual-care and contemporary below-threshold cohorts. The study’s design is a single-arm, prospective, multicenter, open-label pragmatic interventional trial. The goal is to understand the clinical utility and impact of AI-enabled opportunistic liver disease screening.

Sponsored content

Original Scientific Source
American heart journal (PubMed)
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Nanotechnology-Driven 18F-FDG Imaging to Understand the Change in Insulin Sensitivity: Current Evidence, Methodological Gaps, and Translational Challenges.
metabolic-therapy

Nanotechnology-Driven 18F-FDG Imaging to Understand the Change in Insulin Sensitivity: Current Evidence, Methodological Gaps, and Translational Challenges.

Insulin resistance is an important metabolic derangement contributing to the pathogenesis of type 2 diabetes, obesity, metabolic syndrome, and other chronic diseases, underlining the requirement for techniques that enable in vivo analysis of tissue-specific glucose metabolism. 18F-fluorodeoxyglucose positron emission...

10. 11. 2026 Read article →
Cardiometabolic Abnormalities among Normal-Weight Adults: Prevalence and Associated Sociodemographic and Lifestyle Factors in a Large Spanish Cohort.
metabolic-therapy

Cardiometabolic Abnormalities among Normal-Weight Adults: Prevalence and Associated Sociodemographic and Lifestyle Factors in a Large Spanish Cohort.

BACKGROUND: Although body mass index (BMI) is widely used to assess obesity-related health risks, it may fail to detect individuals with normal weight who present with significant cardiometabolic abnormalities. This phenotype, often overlooked in clinical practice, is associated with increased risk of cardiovascular...

30. 10. 2026 Read article →
Advertisement